Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Want to cut your energy bills? Here’s how five experts are doing it 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
NEW YORK, Feb. 28, 2017 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation is scheduled for Tuesday, March 7, 2017 at 9:20 am EST.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
CONTACT: Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
